BUZZ-Street View: Abbott poised for a healthy 2025

Abbott Laboratories ABT.N on Wednesday forecast 2025 profit in line with Wall Street estimates as it expects new medical device launches and growing demand for its glucose monitors to offset a hit from weakness in China and a stronger dollar

Median PT of 28 brokerages covering the stock is $134 - data compiled by LSEG

HEALTHY ON GROWTH AND INNOVATION

J.P. Morgan ("overweight") is bullish on ABT's organic sales growth outlook for 2025 and demand for glucose monitors

RBC ("outperform," PT: $135) says ABT is well-positioned and expects continued growth driven by innovations and a strong product pipeline

TD Cowen ("buy," PT: $135) expects ABT to continue to deliver growth across its various segments, driven by innovation and market expansion

UBS ("buy," PT: $148) says outlook for organic sales growth appears 'conservative'

"We believe the sustainability of ABT’s MedTech business growth trajectory remains underappreciated" - UBS